Freedom Bio is a clinical stage biotech platform with phase 2 programs and 4 pre-clinical programs addressing the biggest shortcoming of first generation psychedelics. The company’s programs are based on 30+ years of work at Dr. John Krystal’s lab at Yale University.
Total raised: $10.5M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.08.2022 | Seed | $10.5M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industr... | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; ... | businessin... |
| 15.02.2023 | LongeVC Invests in Freedom Biosciences | Freedom Biosciences, a US biotechnology platform developing next-generation psychedelic therapeutics... | finsmes.co... |
| 23.08.2022 | Freedom Biosciences Raises $10.5M in Seed Financing | Freedom Biosciences, a San Francisco, CA-based provider of a clinical-stage biotechnology platform t... | finsmes.co... |